<DOC>
	<DOCNO>NCT00665678</DOCNO>
	<brief_summary>Background : Innovation : Over 150,000 soldier currently deploy Iraq part Operation Iraqi Freedom ( OIF ) , 12 % return OIF veteran posttraumatic stress disorder ( PTSD ) . Research group others show lasting neurobiological consequence PTSD , include increase amygdala function decrease medial prefrontal function , verbal declarative memory problem , small hippocampal volume reverse treatment serotonin reuptake inhibitor ( SSRI ) paroxetine anticonvulsant phenytoin . Recently find three month treatment paroxetine PTSD patient result increase hippocampal N-acetyl-aspartate ( NAA ) , marker neuronal integrity , well decrease brain metabolism amygdala reversal stress induce decrease medial prefrontal function . Subjects treat placebo increase NAA , however subsequent treatment three month open label paroxetine result increase NAA level see subject treated paroxetine double-blind phase . Paroxetine associate decrease amygdala metabolism measure positron emission tomography ( PET ) increase medial prefrontal function . Intervening soon trauma critical long-term outcome , since time traumatic memory become indelible resistant treatment . Diminished efficacy treatment time show fact trial Vietnam veterans show less efficacy year . Animal study show pretreatment stress antidepressant reduce chronic behavioral deficit related stress ; although ethical reason study provide pretreatment trauma exposure human . In current VA Merit fund program look effect early intervention Iraq soldier paroxetine , look chronicity PTSD , cognition , cortisol response stress , hippocampal volume NAA , outcomes . We propose add measurement neural correlate paroxetine response use PET . Objectives/Hypotheses : The objective research : - Assess efficacy paroxetine versus placebo treatment early PTSD OIF veterans - Assess effect paroxetine versus placebo amygdala metabolism medial prefrontal response stress OIF veterans PTSD . - Assess ability brain image predict treatment response identify veteran early PTSD benefit early intervention . Hypotheses paroxetine associate : 1 ) improvement PTSD symptom compare placebo base change CAPS baseline three month treatment veteran OIF ; 2 ) increase medial prefrontal function decrease amygdala metabolism veteran OIF . Specific Aims : - Compare paroxetine placebo treatment early PTSD OIF veterans - Measure amygdala metabolism medial prefrontal response stress PET OIF veteran PTSD paroxetine placebo treatment .</brief_summary>
	<brief_title>Neural Correlates Early Intervention Posttraumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description>Study Design : Subjects return Iraq meet criterion early PTSD ( N=160 ) include study recruitment goal 144 completers . A group 80 healthy subject history military service period OIF without history deployment without PTSD 80 healthy subject history deployment without PTSD serve comparator group . All subject undergo baseline image brain PET FDG measurement brain blood flow memory task exposure trauma relate reminder ( slide sound ) MRI baseline psychometric assessment , follow PTSD subject randomize receive paroxetine placebo three month , repeat image assessment . After PTSD subject treat three month open label paroxetine , follow repeat image assessment . This intent treat analysis , therefore subject randomized take least one dose study medication assess three month , regardless whether able stay study medication . This complement currently VA Clinical Trial Merit fund application measure hippocampal volume , NAA , cortisol response stress early intervention paroxetine return Iraq vet early PTSD .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male female veteran age 1850 Returned Iraq Theater within past six month Screen positive PTSD relate Iraq deployment base PTSD Checklist Confirmed PTSD base CAPS , include one month duration symptom Being discharge active service Iraq Provide write informed consent History loss consciousness one minute Psychotropic medication use within previous four week History ( base SCID ) lifetime current alcohol substance abuse/dependence , schizophrenia , schizoaffective disorder , bipolar disorder . Positive urine toxicology screen History predeploymentrelated PTSD partial PTSD base CAPS History PTSD partial PTSD relate prior deployment Serious medical neurological illness Pregnancy History asthma Steroid usage , inhaled oral Seizure disorder Prenatal/perinatal substance exposure trauma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>